Row
C
CYTKAI Stock Diagnostic Report
Cytokinetics posts full data from late-stage trial for lead drug in non-obstructive HCM
Cytokinetics' stock price fell after the company released full data from a Phase 3 trial of its treatment for non-obstructive hypertrophic cardiomyopathy.
View Source Article ↗AI CATALYST SCORE40 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time